Nivolumab-associated cutaneous T-cell lymphoma

Jennifer A Marks; Douglas C Parker; L Crain Garrot; Mary Jo Lechowicz

doi:10.1016/j.jdcr.2020.12.033

Nivolumab-associated cutaneous T-cell lymphoma

JAAD Case Rep. 2021 Jan 10:9:39-41. doi: 10.1016/j.jdcr.2020.12.033. eCollection 2021 Mar.

Authors

Jennifer A Marks¹, Douglas C Parker², L Crain Garrot³, Mary Jo Lechowicz⁴

Affiliations

¹ Department of Internal Medicine, Emory University School of Medicine, Atlanta, Georgia.
² Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.
³ Georgia Cancer Specialists, Northside Hospital Cancer Institute, Atlanta, Georgia.
⁴ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

No abstract available

Keywords: CTCL; CTCL, cutaneous T-cell lymphoma; RCC, renal cell carcinoma; Sezary syndrome; adverse events; immune checkpoint inhibitor; mycosis fungoides; nivolumab.

Publication types

Case Reports